| Market Cap | 234.23M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -4.71M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -19.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -32.00% |
| Dividend | N/A | Price/Book | 15.96 | EPS next 5Y | - | 52W High Chg | -47.00% |
| Recommedations | - | Quick Ratio | - | Shares Outstanding | 13.01M | 52W Low Chg | 10.00% |
| Insider Own | 88.76% | ROA | -24.77% | Shares Float | 1.46M | Beta | -0.54 |
| Inst Own | 0.06% | ROE | -39.72% | Shares Shorted/Prior | 20.24K/41.84K | Price | 18.00 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,038 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 3,850 | Change | -0.33% |
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
